Interview: Citius Pharma (CTXR) $1.74, Chairman Leonard Mazur.
https://youtu.be/vMIy8xWLOKI?t=3699
INSIDER HOLDINGS
POWERPOINT
LIVE CHART
Adding Citius (CTXR) $0.55 to Watch List.
Citius News Archive
MARKET BEAT
TIP RANKS
Disclaimer. Citius Pharma is a client, please see reports for disclosure and...
Citius Pharma (CTXR) Updates Shareholders.
Citius Update Stem Cell Study
Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT)...
Wall Street Showing Love. Hepion Pharma (HEPA), Citius Pharma (CTXR) Raise $166 Million.
Hepion (HEPA) Banked $88 Million Yesterday, Citius (CTXR) Banks $78 Million Today.
We're beginning to believe (and it may be a "brief-belief") that during...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
We're up 370% since adding it to the Biotech Stock Review Watch List...
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous...
Adding Hapbee Tech (HAPB, HAPBF) $0.34 to Biotech Six Pack Watch List.
UPDATE ON BIOTECH SIX PACK, SIX STOCKS WE EXPECT TO DOUBLE.
While the Biotech Stock Review was launched in 2002, the "Biotech 6-Pack, 6 Stocks...
Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...
Completion of Enrollment Remains on Track for Q1, 2024
"While we recently had fireworks, we could be looking at real fireworks in the coming year....
Ouch…Omniq (OMQS).
We had fun with this for a good year, doubling after we found it.
Adding OmniQ (OMQS) $5.00 to the Watch List.
LIVE QUOTE
Then it...
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine Kaufman
Provention Bio’s new injectable drug was recommended by an FDA committee...
Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of Citius' novel...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
Eric Sprott, on Who is the Next Eric Sprott!
To say Eric Sprott has left a legendary mark on the world of mining investment would...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
